Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 75 versus RENOVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 75 versus RENOVIST.
HYPAQUE-M,75% vs RENOVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast due to high iodine content. It increases the density of vascular structures and tissues, allowing visualization of anatomical structures during imaging procedures.
RENOVIST is a radiocontrast agent that enhances imaging by attenuating X-rays due to its iodine content. It acts by increasing the density of blood vessels and tissues, improving contrast in radiographic studies.
1.2-1.5 mL/kg IV as a single dose for CT enhancement; maximum 150 mL per procedure.
0.5-1 mg/kg intravenously daily
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria).
Terminal half-life: 12 hours; in renal impairment (CrCl <30 mL/min) prolonged to 24-36 hours; dose adjustment required
Renal excretion: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Renal: 70% as unchanged drug; fecal: 20% as metabolites; biliary: 10%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent